

Giampaolo Perna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6303249/giampaolo-perna-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190
papers

4,732
citations

39
h-index

56
g-index

203
ext. papers

5,454
ext. citations

4.6
avg, IF

5.34
L-index

#	Paper	IF	Citations
190	Prediction of illness remission in patients with Obsessive-Compulsive Disorder with supervised machine learning. <i>Journal of Affective Disorders</i> , 2022 , 296, 117-125	6.6	0
189	Predicting New-Onset Psychiatric Disorders Throughout the COVID-19 Pandemic: A Machine Learning Approach.. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022 , appineuropsych21060148	2.7	1
188	First-onset major depression during the COVID-19 pandemic: A predictive machine learning model.. <i>Journal of Affective Disorders</i> , 2022 , 310, 75-86	6.6	0
187	Experimental Drugs for Panic Disorder: An Updated Systematic Review. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 441-459	3	1
186	751 Heart Rate and Heart Rate Variability During Sleep As Biomarkers for Depression. <i>Sleep</i> , 2021 , 44, A293-A293	1.1	
185	253 Better and faster automatic sleep staging with artificial intelligence. <i>Sleep</i> , 2021 , 44, A102-A102	1.1	
184	Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine. <i>Current Pharmaceutical Design</i> , 2021 , 27, 3293-3304	3.3	4
183	Expert opinion in panic disorder: The impact of COVID-19-related fears, protective devices, and lockdown on panic and agoraphobia. <i>Personalized Medicine in Psychiatry</i> , 2021 , 27-28, 100080	1.1	0
182	Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health. <i>Personalized Medicine in Psychiatry</i> , 2021 , 27-28, 100077	1.1	
181	Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting. <i>Psychiatry Research</i> , 2021 , 295, 113556	9.9	0
180	Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 107, 110208	5.5	3
179	Oxidative Stress in the Early Stage of Psychosis. <i>Current Topics in Medicinal Chemistry</i> , 2021 , 21, 1457-1470	3.0	3
178	Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive-compulsive disorder. <i>Journal of Psychosomatic Research</i> , 2021 , 150, 110604	4.1	1
177	Relapse prevention in panic disorder with pharmacotherapy: where are we now?. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1699-1711	4	4
176	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. <i>Revista Brasileira De Psiquiatria</i> , 2020 , 42, 317-321	2.6	9
175	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 554-584	3	17
174	Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables. <i>Psychiatry Investigation</i> , 2020 , 17, 193-206	3.1	11

173	Personalized Clinical Approaches to Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1191, 489-521	3.6	4
172	Heart rate variability: Can it serve as a marker of mental health resilience?: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. <i>Journal of Affective Disorders</i> , 2020 , 263, 754-761	6.6	33
171	Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday 'real world' clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020 , 24, 83-87	2.4	20
170	Impact of respiratory protective devices on respiration: Implications for panic vulnerability during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2020 , 277, 772-778	6.6	11
169	'Precision' or 'personalized' psychiatry: different terms - same content?. <i>Fortschritte Der Neurologie Psychiatrie</i> , 2020 , 88, 759-766	0.5	2
168	Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-Episode Major Depression: An Exploratory Study in the Real World Clinical Practice. <i>Brain Sciences</i> , 2020 , 10,	3.4	8
167	Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice. <i>Microbial Biotechnology</i> , 2020 , 14, 336-342	3.3	19
166	COVID-19 and panic disorder: clinical considerations for the most physical of mental disorders. <i>Revista Brasileira De Psiquiatria</i> , 2020 , 43, 110-111	2.6	3
165	The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. <i>Frontiers in Psychiatry</i> , 2019 , 10, 294	5	23
164	A Novel Ensemble-Based Machine Learning Algorithm to Predict the Conversion From Mild Cognitive Impairment to Alzheimer's Disease Using Socio-Demographic Characteristics, Clinical Information, and Neuropsychological Measures. <i>Frontiers in Neurology</i> , 2019 , 10, 756	4.1	28
163	Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 1957-1970	3.1	6
162	Common and different neural markers in major depression and anxiety disorders: A pilot structural magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019 , 290, 42-50	2.9	16
161	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. <i>Current Pharmaceutical Design</i> , 2019 , 25, 381-387	3.3	15
160	Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. <i>Psychiatry Investigation</i> , 2019 , 16, 50-58	3.1	10
159	When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia 2019 , 349-367		2
158	A clinically-translatable machine learning algorithm for the prediction of Alzheimer's disease conversion: further evidence of its accuracy via a transfer learning approach. <i>International Psychogeriatrics</i> , 2019 , 31, 937-945	3.4	18
157	The role of spatial store and executive strategy in spatial working memory: a comparison between patients with obsessive-compulsive disorder and controls. <i>Cognitive Neuropsychiatry</i> , 2019 , 24, 14-27	2	1
156	Mental health professionals' attitudes towards mental illness: professional and cultural factors in the INTER NOS study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 325-339	5.1	14

155	A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 1555-1573	4.3	35
154	Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. <i>Therapeutic Advances in Drug Safety</i> , 2018 , 9, 237-256	3.5	83
153	Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 221-228	6.2	8
152	Atypical Antipsychotics in Major Depressive Disorder 2018 , 257-268		2
151	Precision Psychiatry: Personalized Clinical Approach to Depression 2018 , 245-261		
150	Personality biomarkers of pathological gambling: A machine learning study. <i>Journal of Neuroscience Methods</i> , 2018 , 294, 7-14	3	11
149	Features of mood associated with high body weight in females with fibromyalgia. <i>Comprehensive Psychiatry</i> , 2018 , 80, 57-64	7.3	6
148	Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1357-1368	4	10
147	Commentary: Cognitive Behavioral Therapy vs. Eye Movement Desensitization and Reprocessing for Treating Panic Disorder: A Randomized Controlled Trial. <i>Frontiers in Psychology</i> , 2018 , 9, 1061	3.4	2
146	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 617-623	4.3	2
145	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. <i>Current Neuropharmacology</i> , 2018 , 16, 583-606	7.6	41
144	Reduced cortical thickness and increased gyrification in generalized anxiety disorder: a 3 T MRI study. <i>Psychological Medicine</i> , 2018 , 48, 2001-2010	6.9	24
143	Is panic disorder a disorder of physical fitness? A heuristic proposal. <i>F1000Research</i> , 2018 , 7, 294	3.6	8
142	Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	99
141	Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder. <i>Archives of Suicide Research</i> , 2017 , 21, 100-112	2.3	34
140	Mediation effect of recent loss events on weight gain in obese people who experienced childhood parental death or separation. <i>Journal of Health Psychology</i> , 2017 , 22, 101-110	3.1	2
139	Personalized Medicine in Psychiatry: Back to the Future. <i>Personalized Medicine in Psychiatry</i> , 2017 , 1-2, 1	1.1	4
138	Latent classes of emotional and behavioural problems in epidemiological and referred samples and their relations to DSM-IV diagnoses. <i>European Child and Adolescent Psychiatry</i> , 2017 , 26, 549-557	5.5	15

137	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. <i>CNS Spectrums</i> , 2017 , 22, 342-347 ¹⁸	26
136	Personalized medicine in panic disorder: where are we now? A meta-regression analysis. <i>Personalized Medicine in Psychiatry</i> , 2017 , 1-2, 26-38	1.1 4
135	Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes. <i>Psychiatry Investigation</i> , 2017 , 14, 8-15	3.1 3
134	Management of Treatment-Resistant Panic Disorder. <i>Current Treatment Options in Psychiatry</i> , 2017 , 4, 371-386	3.1 14
133	Does gender influence cognitive function in non-psychotic depression?. <i>Personalized Medicine in Psychiatry</i> , 2017 , 4-6, 25-31	1.1 2
132	The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. <i>International Review of Psychiatry</i> , 2017 , 29, 425-435	3.6 20
131	Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2017 , 8, 148 5	91
130	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3 21
129	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. <i>BioMed Research International</i> , 2017 , 2017, 3084859	3 14
128	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 65-92	2.6 19
127	Childhood adversities in patients with fibromyalgia: are they related to comorbid lifetime major depression?. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 105, 112-118	2.2 3
126	An update of safety of clinically used atypical antipsychotics. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1329-47	4.1 90
125	Is there cardiac risk in panic disorder? An updated systematic review. <i>Journal of Affective Disorders</i> , 2016 , 194, 38-49	6.6 17
124	The HPA axis in bipolar disorder: Systematic review and meta-analysis. <i>Psychoneuroendocrinology</i> , 2016 , 63, 327-42	5 194
123	The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2016 , 195, 105-18	6.6 50
122	Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. <i>Current Psychiatry Reports</i> , 2016 , 18, 23	9.1 37
121	Effect of family structure and TPH2 G-703T on the stability of dysregulation profile throughout adolescence. <i>Journal of Affective Disorders</i> , 2016 , 190, 576-584	6.6 6
120	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2016 , 22, 5144-5162	3.3 16

119	S-Adenosyl-L-Methionine for Major Depressive Disorder 2016 , 847-854		
118	Panic Disorder, Is It Really a Mental Disorder? From Body Functions to the Homeostatic Brain 2016 , 93-112		
117	Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders 2016 , 305-316		
116	Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 1827-36	3.1	12
115	Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 551	6.3	13
114	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 719-35	3.1	57
113	Does the "" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2016 , 12, 142-157	3.2	11
112	Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression. <i>Neural Plasticity</i> , 2016 , 2016, 8457612	3.3	47
111	Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 241	6.3	34
110	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. <i>Frontiers in Psychiatry</i> , 2016 , 7, 138	5	65
109	A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016 , 15, 35-44	2.6	37
108	Comments on "Heart rate and respiratory response to doxapram in patients with panic disorder". <i>Psychiatry Research</i> , 2016 , 239, 362-3	9.9	1
107	Role of worry in patients with chronic tinnitus and sensorineural hearing loss: a preliminary study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016 , 273, 4145-4151	3.5	6
106	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 483-95	4.3	16
105	Psychiatric Disorders and Childhood Parental Loss in Obesity: Relationship with the Mode of Weight Gain. <i>Journal of Loss and Trauma</i> , 2016 , 21, 213-224	3.9	4
104	Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016 , 20, 224-31	2.4	6
103	Is panic disorder associated with clinical severity of fibromyalgia? A preliminary study in a tertiary-care centre. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S99-105	2.2	1
102	Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 1111-30	6.3	51

101	Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: an exploratory study. <i>Comprehensive Psychiatry</i> , 2015 , 58, 82-7	7.3	27
100	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). <i>Journal of Affective Disorders</i> , 2015 , 178, 112-20	6.6	14
99	Prevalence and clinical features associated to bipolar disorder-migraine comorbidity: a systematic review. <i>Comprehensive Psychiatry</i> , 2015 , 56, 1-16	7.3	20
98	The role of melatonin in mood disorders. <i>ChronoPhysiology and Therapy</i> , 2015 , 65		7
97	Novel investigational therapeutics for panic disorder. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 491-505	5.9	22
96	Laboratory, clinical and therapeutic features of respiratory panic disorder subtype. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015 , 14, 627-35	2.6	16
95	Self-reported quality of life and clinician-rated functioning in mood and anxiety disorders: relationships and neuropsychological correlates. <i>Comprehensive Psychiatry</i> , 2014 , 55, 979-88	7.3	13
94	Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2014 , 8, 30-7		18
93	Effect of the serotonin transporter gene and of environment on the continuity of anxiety and depression traits throughout adolescence. <i>Epidemiology and Psychiatric Sciences</i> , 2014 , 23, 399-409	5.1	7
92	Childhood trauma, temperament, and character in subjects with major depressive disorder and bipolar disorder. <i>Journal of Nervous and Mental Disease</i> , 2014 , 202, 695-8	1.8	13
91	Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder. <i>Revista Brasileira De Psiquiatria</i> , 2014 , 36, 125-30	2.6	38
90	Are respiratory abnormalities specific for panic disorder? A meta-analysis. <i>Neuropsychobiology</i> , 2014 , 70, 52-60	4	25
89	Panic and the brainstem: clues from neuroimaging studies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1049-56	2.6	17
88	Baseline respiratory parameters in panic disorder: a meta-analysis. <i>Journal of Affective Disorders</i> , 2013 , 146, 158-73	6.6	42
87	Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone. <i>Acta Neuropsychiatrica</i> , 2013 , 25, 119-21	3.9	2
86	The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 12458-83	6.3	57
85	Insomnia as a predictor of high-lethality suicide attempts. <i>International Journal of Clinical Practice</i> , 2013 , 67, 1311-6	2.9	68
84	S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. <i>Scientific World Journal, The</i> , 2013 , 204649	2.2	15

83	Understanding anxiety disorders: the psychology and the psychopathology of defence mechanisms against threats. <i>Rivista Di Psichiatria</i> , 2013 , 48, 73-5	3.1	8
82	Efficacy and safety of long acting injectable atypical antipsychotics: a review. <i>Current Clinical Pharmacology</i> , 2013 , 8, 256-64	2.5	17
81	Effects of cigarette smoking on neuropsychological performance in mood disorders: a comparison between smoking and nonsmoking inpatients. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, e130-6	4.6	16
80	The somatic marker affecting decisional processes in obsessive-compulsive disorder. <i>Cognitive Neuropsychiatry</i> , 2012 , 17, 177-90	2	24
79	The Relationships between Cholesterol and Suicide: An Update 2012 , 2012, 387901		39
78	Temperament, character and anxiety sensitivity in panic disorder: a high-risk study. <i>Psychopathology</i> , 2012 , 45, 300-4	3.4	4
77	Emerging drugs for panic disorder. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 631-45	3.7	20
76	Novel antidepressants and panic disorder: evidence beyond current guidelines. <i>Neuropsychobiology</i> , 2011 , 63, 1-7	4	11
75	Is there a hypersensitive visual alarm system in panic disorder?. <i>Psychiatry Research</i> , 2011 , 187, 387-91	9.9	27
74	Cardiorespiratory response to physical exercise and psychological variables in panic disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011 , 33, 385-9	2.6	10
73	Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 621-37	3.1	9
72	Tradução e adaptação transcultural do Questionário de Atividade Física Habitual. <i>Revista De Psiquiatria Clínica</i> , 2010 , 37, 16-22	0.8	14
71	Dizziness, migrainous vertigo and psychiatric disorders. <i>Journal of Laryngology and Otology</i> , 2010 , 124, 285-90	1.8	25
70	Panic disorder respiratory subtype: psychopathology, laboratory challenge tests, and response to treatment. <i>Harvard Review of Psychiatry</i> , 2010 , 18, 220-9	4.1	50
69	Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder patients. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 357-63	3.8	8
68	Acoustic startle response in panic disorder. <i>Psychiatry Research</i> , 2010 , 176, 254-6	9.9	6
67	Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1167-81	4	19
66	Freezing reaction in panic disorder patients associated with anticipatory anxiety. <i>Depression and Anxiety</i> , 2009 , 26, 917-21	8.4	32

65	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 1-18	2.2	39
64	Clonazepam in the treatment of psychiatric disorders: an update. <i>International Clinical Psychopharmacology</i> , 2006 , 21, 131-42	2.2	31
63	Anxiety sensitivity in children of panic disorder patients. <i>Child Psychiatry and Human Development</i> , 2005 , 35, 315-24	3.3	15
62	Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. <i>Neuropsychopharmacology</i> , 2005 , 30, 2230-5	8.7	81
61	Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. <i>Pharmacopsychiatry</i> , 2004 , 37, 206-10	2	35
60	Panic disorder: from respiration to the homeostatic brain. <i>Acta Neuropsychiatrica</i> , 2004 , 16, 57-67	3.9	44
59	Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. <i>American Journal of Medical Genetics Part A</i> , 2004 , 129B, 41-3		17
58	Language of dyspnea in panic disorder. <i>Depression and Anxiety</i> , 2004 , 20, 32-8	8.4	31
57	Selective serotonin re-uptake inhibitors beyond psychiatry: are they useful in the treatment of severe, chronic, obstructive pulmonary disease?. <i>Depression and Anxiety</i> , 2004 , 20, 203-4	8.4	11
56	Smoking and respiratory irregularity in panic disorder. <i>Biological Psychiatry</i> , 2004 , 56, 393-8	7.9	28
55	Comparison of 35% carbon dioxide reactivity between panic disorder and eating disorder. <i>Psychiatry Research</i> , 2004 , 125, 277-83	9.9	16
54	Anxiety sensitivity and modulation of the serotonergic system in patients with PD. <i>Journal of Anxiety Disorders</i> , 2004 , 18, 423-31	10.9	7
53	Approximate entropy of respiratory patterns in panic disorder. <i>American Journal of Psychiatry</i> , 2004 , 161, 79-87	11.9	100
52	Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 277-82	1.7	26
51	Pregnancy and respiratory nocturnal panic attacks. <i>Canadian Journal of Psychiatry</i> , 2003 , 48, 573-4	4.8	3
50	Serotonergic modulation of the balance system in panic disorder: an open study. <i>Depression and Anxiety</i> , 2003 , 17, 101-6	8.4	23
49	Anxiety sensitivity and 35% CO2 reactivity in patients with panic disorder. <i>Journal of Psychosomatic Research</i> , 2003 , 54, 573-7	4.1	21
48	Neurosteroid secretion in panic disorder. <i>Psychiatry Research</i> , 2003 , 118, 107-16	9.9	99

47	Vulnerability to 35% CO ₂ of panic disorder patients with a history of respiratory disorders. <i>Psychiatry Research</i> , 2003 , 120, 125-30	9.9	12
46	The effect of one-week treatment with venlafaxine on 35% CO ₂ hyperreactivity in patients with panic disorder: an open study. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 106-8	1.7	8
45	Respiration in children at risk for panic disorder. <i>Archives of General Psychiatry</i> , 2002 , 59, 185-6		22
44	Antipanic drug modulation of 35% CO ₂ hyperreactivity and short-term treatment outcome. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 300-8	1.7	42
43	Panic disorder: the role of the balance system. <i>Journal of Psychiatric Research</i> , 2001 , 35, 279-86	5.2	61
42	A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. <i>Pharmacopsychiatry</i> , 2001 , 34, 85-90	2	53
41	The 35% CO ₂ hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 262-7	1.7	26
40	Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation. <i>Psychoneuroendocrinology</i> , 2000 , 25, 301-10	5	20
39	Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. <i>Psychiatry Research</i> , 1999 , 89, 21-7	9.9	23
38	A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO ₂ challenge. <i>Biological Psychiatry</i> , 1999 , 45, 365-7	7.9	21
37	A segregation study of panic disorder in families of panic patients responsive to the 35% CO ₂ challenge. <i>Biological Psychiatry</i> , 1999 , 46, 815-20	7.9	22
36	Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 379-84	4.6	26
35	Plasma concentrations of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha in anorexia and bulimia nervosa. <i>Psychoneuroendocrinology</i> , 1998 , 23, 439-47	5	32
34	Growth hormone response to growth hormone-releasing hormone stimulation in obsessive-compulsive disorder. <i>Psychiatry Research</i> , 1998 , 81, 293-9	9.9	4
33	CO ₂ -induced panic attacks: a twin study. <i>American Journal of Psychiatry</i> , 1998 , 155, 1184-8	11.9	78
32	CO ₂ challenge in nonclinical subjects. <i>American Journal of Psychiatry</i> , 1997 , 154, 886-7	11.9	6
31	Asthma and panic attacks. <i>Biological Psychiatry</i> , 1997 , 42, 625-30	7.9	75
30	Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. <i>Biological Psychiatry</i> , 1997 , 42, 976-81	7.9	59

29	Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. <i>Biological Psychiatry</i> , 1997 , 42, 889-97	7.9	42
28	Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration. <i>Psychiatry Research</i> , 1997 , 69, 163-8	9.9	12
27	Noradrenergic receptor sensitivity in obsessive-compulsive disorders: I. Growth hormone response to clonidine stimulation. <i>Psychiatry Research</i> , 1997 , 69, 155-62	9.9	14
26	The 35% CO2 challenge test in patients with social phobia. <i>Psychiatry Research</i> , 1997 , 71, 41-8	9.9	68
25	Panic attacks: a twin study. <i>Psychiatry Research</i> , 1997 , 66, 69-71	9.9	48
24	Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 97-101	1.7	44
23	Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 173-8	1.7	36
22	Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. <i>American Journal of Psychiatry</i> , 1996 , 153, 1060-4	11.9	60
21	Citalopram and panic disorder. <i>Depression and Anxiety</i> , 1996 , 4, 253	8.4	
20	Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. <i>Psychoneuroendocrinology</i> , 1995 , 20, 1-9	5	33
19	Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. <i>Psychoneuroendocrinology</i> , 1995 , 20, 11-9	5	20
18	The 35% CO2 challenge in panic disorder: optimization by receiver operating characteristic (ROC) analysis. <i>Journal of Psychiatric Research</i> , 1995 , 29, 111-9	5.2	88
17	Menstrual cycle-related sensitivity to 35% CO2 in panic patients. <i>Biological Psychiatry</i> , 1995 , 37, 528-32	7.9	37
16	T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. <i>Psychiatry Research</i> , 1995 , 59, 43-50	9.9	21
15	T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa. <i>Psychiatry Research</i> , 1995 , 59, 51-6	9.9	18
14	Hypersensitivity to inhalation of carbon dioxide and panic attacks. <i>Psychiatry Research</i> , 1995 , 57, 267-73	9.9	55
13	35% CO2 challenge in panic and mood disorders. <i>Journal of Affective Disorders</i> , 1995 , 33, 189-94	6.6	79
12	Alpha-2-adrenoceptor sensitivity in heroin addicts with and without previous attention deficit disorder/hyperactivity and conduct disorder. <i>Neuropsychobiology</i> , 1994 , 30, 15-9	4	16

11	Subclinical impairment of lung airways in patients with panic disorder. <i>Biological Psychiatry</i> , 1994 , 36, 601-5	7.9	15
10	Plasma interleukin-1 beta concentrations in panic disorder. <i>Psychiatry Research</i> , 1994 , 54, 135-42	9.9	45
9	Carbon dioxide/oxygen challenge test in panic disorder. <i>Psychiatry Research</i> , 1994 , 52, 159-71	9.9	133
8	Pharmacologic Effect of Toloxatone on Reactivity to the 35% Carbon Dioxide Challenge. <i>Journal of Clinical Psychopharmacology</i> , 1994 , 14, 414-418	1.7	21
7	Prevalence of respiratory diseases in patients with panic and obsessive compulsive disorders. <i>Anxiety</i> , 1994 , 1, 100-1		9
6	DSM-III-R personality disorders in panic disorder. <i>Journal of Anxiety Disorders</i> , 1993 , 7, 153-161	10.9	9
5	Psychoimmunoendocrine aspects of panic disorder. <i>Neuropsychobiology</i> , 1992 , 26, 12-22	4	60
4	DSM-III-R personality disorders in panic and obsessive-compulsive disorder: a comparison study. <i>Comprehensive Psychiatry</i> , 1991 , 32, 450-7	7.3	28
3	Anxiety, depression, and suicide: epidemiology, pathophysiology, and prevention93-100		2
2	Respiration and Anxiety251-267		
1	A Novel Ensemble-Based Machine Learning Algorithm To Predict The Conversion From Mild Cognitive Impairment To Alzheimer's Disease Using Socio-demographic Characteristics, Clinical Information And Neuropsychological Measures		1